Race-modified equations contribute to disparity in partial nephrectomy use in black patients
July 10th 2023“Our findings show that race-modified equations account for some but not all of the disparity in partial nephrectomy use. We need to keep searching for answers to ensure people of all races receive appropriate care," said Christopher Weight, MD.
Analysis further links prostate cancer drug class with cognitive and functional toxicity
July 5th 2023“To our knowledge, these results are the first to suggest an association between second-generation [antiandrogens] and cognitive and functional toxic effects based on data from prospective [randomized controlled trials],” the investigators wrote.
Flotufolastat F 18 scans show high degree of inter- and intra-reader agreement in prostate cancer
July 3rd 2023"The high reproducibility of reader results across all regions is clinically valuable, with the potential to influence patient management prior to surgery for patients with newly diagnosed disease," says Phillip H. Kuo, MD, PhD.
Timing between 177Lu-PSMA doses shows no impact on survival in patients with mCRPC
June 30th 2023"Personalized dosing allowed one-third of the men in this study to have treatment breaks while still achieving the same progression-free and overall survival outcomes they would have if they received continuous treatment," says Andrew Nguyen, MBBS, FRACP, AANMS.
Diagnostics company opens new facility to scale up production of IsoPSA test for prostate cancer
June 29th 2023The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.